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Development of veterinary subunit vaccines comes with a spectrum of challenges, such
as the choice of adjuvant, antigen delivery vehicle, and optimization of dosing strategy.
Over the years, our laboratory has largely focused on investigating silica vesicles (SVs)
for developing effective veterinary vaccines for multiple targets. Rhipicephalus microplus
(cattle tick) are known to have a high impact on cattle health and the livestock industry
in the tropical and subtropical regions. Development of vaccine using Bm86 antigen
against R. microplus has emerged as an attractive alternative to control ticks. In this
study, we have investigated the biodistribution of SV in a live animal model, as well as
further explored the SV ability for vaccine development. Rhodamine-labeled SV-140-C18
(Rho-SV-140-C18) vesicles were used to adsorb the Cy5-labeled R. microplus Bm86
antigen (Cy5-Bm86) to enable detection and characterization of the biodistribution of
SV as well as antigen in vivo in a small animal model for up to 28 days using optical
fluorescence imaging. We tracked the in vivo biodistribution of SVs and Bm86 antigen at
different timepoints (days 3, 8, 13, and 28) in BALB/c mice. The biodistribution analysis
by live imaging as well as by measuring the fluorescent intensity of harvested organs
over the duration of the experiment (28 days) showed greater accumulation of SVs at the
site of injection. The Bm86 antigen biodistribution was traced in lymph nodes, kidney,
and liver, contributing to our understanding how this delivery platform successfully elicits
antibody responses in the groups administered antigen in combination with SV. Selected
tissues (skin, lymph nodes, spleen, kidney, liver, and lungs) were examined for any cellular
abnormalities by histological analysis. No adverse effect or any other abnormalities were
observed in the tissues.
Keywords: silica vesicles, adjuvants, Bm86 antigen, biodistribution, in vivo imaging, live animal imaging, immune
response
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INTRODUCTION
The beef cattle industry makes an important contribution to the
global economy. In the recent years (2017–2018), it accounted
for around 20% ($12.3 billion) of the total gross value of farm
production. Ticks and tick-borne diseases have a serious impact
on the global stock farming industry by negatively affecting
the cattle health and production. Different approaches such
as chemical acaricides and vaccines have been investigated to
control cattle ticks. However, because of environmental and
chemical-resistance issues associated with the use of acaricides,
alternative solutions are required. One of the potential solutions
is vaccination, which is increasingly preferred and is sought after
to provide a long-term solution for more effective management
of this pest.
The Bm86 antigen is a membrane-bound glycoprotein
distributed mainly on the surface of the digestive tract of
Rhipicephalus (Boophilus) microplus females and the principal
component in cattle tick vaccine that can induce protective
immune responses against this parasite. Compared with naturally
induced immunity to B. microplus, the immune response elicited
by Bm86 is regulated by host antibodies that interact with
and damages (Willadsen and Bird, 1995). The recombinant
Bm86-based tick vaccines have shown their efficacy for the
control of cattle ticks, B. microplus and Rhipicephalus annulatus
(Bastos et al., 2010; Sloat et al., 2010; Rodríguez-Valle et al.,
2012). Therefore, it is crucial to develop more effective vaccine
adjuvants/carrier that can elicit strong and sustained antibody
responses against Bm86 antigen.
In the past decade, mesoporous silica nanoparticles (MSNs)
have emerged as self-adjuvanting vaccine carriers with
remarkable potential for the delivery of variety of antigens
(Mody et al., 2013). MSNs are reported not only as biodegradable
and biocompatible material but are also easy to modify and
have low production costs. Our research over the last decade
has focused on developing a platform technology using MSNs
as antigen carriers and adjuvants for developing a nanovaccine
with reduced number of injections, induction of long-term
immune responses, and improved dose storage capacity. We
have thoroughly investigated the potential of one class of MSNs,
silica vesicles (SVs), as self-adjuvanting antigen carriers to
develop successful vaccine delivery systems targeting bovine viral
diarrhea virus-1 (mucosal disease) (Mahony et al., 2013, 2014;
Mody et al., 2014a,b): Anaplasma marginale (anaplasmosis)
(Zhang et al., 2016) and Theileria parva (East Coast Fever).
In all of our studies, SVs successfully delivered the antigen of
interest and initiated both humoral and cell-mediated immune
responses. However, knowledge of the biodistribution and fate of
this promising delivery technology remain unknown.
In this study, for the first time, we have investigated the
biodistribution, fate, and immunogenicity of a single dose of
SV adsorbed with Bm86 protein antigen. Using SV carriers and
Bm86 antigen that were labeled with fluorescent makers and live
animal (in vivo) and organ (ex vivo) imaging, we demonstrated
the persistence of the carrier at the site of injection, whereas the
antigen was continuously trafficked to the lymph nodes in the
most immunologically responsive groups. This study provides
important insights into the fate and safety of silica nanoparticles
when used in vaccine applications. The study also suggests that
these particles augment specific immune responses by acting as
reservoir for continuous release of antigen.
MATERIALS AND METHODS
Bm86 Production
A synthetic open reading frame for Bm86 antigen expressed in
insect was assembled by GeneArt AG (Life Technologies) and
cloned into pMK-RQ (kanR) using the cloning sites Sfil/Sfil.
The purified plasmid DNA was transformed into Escherichia
coli Top10 chemically competent cells (Invitrogen) to promote
propagation and the transformed E. coli was cultivated overnight
on LB agar plates containing 100µg/mL ampicillin at 37◦C.
Single colonies conferring ampicillin resistance were selected
and grown overnight in 10mL of LB containing 100µg/mL
ampicillin with vigorous shaking at 37◦C. Cells were harvested
by centrifugation at 10,000 g, and pMK-RQBM86 vector was
purified from the overnight culture using a Qiaprep spin
miniprep kit (Qiagen). The 1890bp Bm86 fragment was released
from the pMK-RQ vector by restriction endonuclease digestion,
using BamHI and HindIII restriction enzymes (NEB) following
manufacturer’s instructions. The Bm86 gene fragment was
successfully ligated into the pFASTBAC1 expression vector and
transformed into top 10 chemically competent cells (Invitrogen),
followed by overnight cultivation at 37◦C on LB plates containing
100µg/mL ampicillin. The final plasmid construct was verified
by DNA sequencing to confirm the correct insertion of the Bm86
open reading frame.
Virus Seed Stock
Log-phase Spodoptera frugiperda Sf 9 (ATCC R© CRL-1711) cells
were seeded at 1 × 106 cells/well in Sf-900TM III SFM medium
(Life Technologies, Scoresby, Victoria, Australia), in each well
of a 6-well dish (Nunc, Life Technologies, Scoresby, Victoria,
Australia), and allowed to adhere (1 h, 27◦C). Bacmid DNA
(1 µg) was added to prediluted ExpiFectamineTM Transfection
Reagent (Life Technologies, Scoresby, Victoria, Australia)
prepared according to manufacturer’s instructions. Following
incubation of the ExpiFectamineTM/Bacmid DNA complex
[room temperature (RT), 5min], the DNA–lipid mixture was
added dropwise onto the Sf9 cells and incubated for 72 h at 27◦C.
Once the cells appeared infected, the virus was harvested from
the culture medium by centrifugation (500 g, 5min). The cleared
supernatant was transferred to a sterile tube and stored at 4◦C,
protected from light.
Virus Amplification
Amplification of the Bm86 recombinant baculovirus was carried
out using a shake flask format, with Sf 9 cells seeded at 1 × 106
cells/mL. An appropriate volume of the recombinant virus seed
stock was used as inoculum. Both cell density and viability were
monitored, and the culture supernatant was harvested when the
cells were infected with the virus.
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Expression
The expression culture was set up using the following infection
parameters. Briefly, 2.5 L of Trichoplusia ni cells High FiveTM
cells (Life Technologies, Scoresby, Victoria, Australia) was
seeded at midlog phase in an Optimum GrowthTM (Genesearch,
Queensland, Australia) 5-L flask (135 rpm, 21◦C) and infected
with 1.5× 106 cells/mL of BM86 recombinant baculovirus. Cells
were harvested at 120 h postinfection and separated from the
supernatant by centrifugation at 9,000 g for 20 min.
Purification
Supernatant from the expression culture was concentrated to
400mL using a Hydrosart ultrafiltration cassette (Sartorius
Australia Pty Ltd., Dandenong South, Victoria, Australia) 30-kDa
nominal molecular weight cutoff. The concentrated supernatant
was passed through a 0.45-µmfilter (MerckMillipore, Bayswater,
Victoria, Australia) and purified on an AKTA Pure FPLC System
(GE Healthcare Life Sciences, USA) using immobilized affinity
chromatography and purified under native conditions. Using a
HiScale 26/20, 20mL Ni Sepharose Excel (GE Healthcare Life
Sciences, USA), the concentrated supernatant was loaded at a
flow rate of 13 mL/min. To remove non–specifically bound
proteins, the column was washed with 20 column volumes
of wash buffer (20mM sodium phosphate, 500mM NaCl,
20mM Imidazole, pH 8.0). The recombinant Bm86 protein
was eluted in native elution buffer (five column volumes, 50%
elution buffer, 20mM sodium phosphate, 500mMNaCl, 500mM
imidazole, pH 8.0, and five column volumes of 100% elution
buffer). Fractions (2mL) were collected during the elution steps
and monitored by 10% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS–PAGE). Eluted fractions containing
high-purity Bm86 were pooled and desalted into phosphate-
buffered saline (PBS) using HiPrep 26/10 desalting columns
(GE Healthcare Life Sciences, USA) following manufacturer’s
guidelines. The buffer exchanged samples were concentrated
using an Amicon R© Ultra-15 Centrifugal Filter with a 30-kDa
molecular weight cutoff (Merck Millipore, Bayswater, Victoria,
Australia). The sample was filter-sterilized with a 0.22-µm filter
(Merck Millipore, Bayswater, Victoria, Australia) and stored at
−80◦C. An endotoxin test was carried out on the final sample
using an Endosafe-PTS Limulus Amebocyte Lysate test kit
(Charles River Laboratory Australia, Kilsyth, Victoria, Australia).
Preparation of Rhodamine-Labeled
SV-140-C18 and Cy5 Labeled Bm86 Antigen
The Rhodamine-labeled SV-140 (diameter 50 nm, wall thickness
6 nm, perforated by pores with an entrance size 16 nm and
total pore volume of 0.934 cm3 g−1) were prepared and labeled
as described in Mody et al. (2014a), Zhang et al. (2014), and
Zhang et al. (2016). Cy5-labeled Bm86 (Cy5-Bm86) was prepared
using the Abcam’s manufacturer protocol (ab188288–Cy5 Fast
Conjugation Kit).
Adsorption of Cy5 Bm86 Antigen on
Rho-SV-140-C18 and Western Hybridization
Adsorption reactions were set up as previously described (Mody
et al., 2016), and the amount of unbound Bm86 protein was
assessed by electrophoresis of the supernatants and the particles
on SDS–PAGE gels (Supplementary Methods). Following SDS–
PAGE electrophoresis, the Cy5-labeled Bm86 protein in the
nanovaccine formulations was detected using Western blot
hybridization as previously described (Zhang et al., 2016).
Cellular Uptake of Cy5 Bm86 Antigen and
Rho-SV-140-C18 Using Confocal
Microscopy
Cy5-Bm86 was adsorbed on Rho-SV-140-C18 as described above.
Murine macrophage-like RAW264.7 cells (kindly donated by Dr.
Barbara Rolfe from the Australian Institute for Bioengineering
and Nanotechnology, The University of Queensland) were
maintained in Dulbecco modified eagle medium supplemented
with 10% fetal bovine serum at 37◦C in a 5% CO2 incubator
using standard cell culture procedures. For cellular uptake
assays, 1 × 105 RAW 264.7 cells were allowed to attach on
sterile microscope coverslip chambers at 37◦C for 24 h and
then exposed to Cy5-Bm86 antigen adsorbed to Rho-SV-140-
C18, Cy5-Bm86 antigen, Cy5 Bm86 antigen adsorbed to Rho-
SV-140-C18 plus Montanide ISA 206 (Seppic), and Cy5-Bm86
antigen plus Montanide ISA 206, Rho-SV-140-C18. Montanide
ISA 206 VG adjuvant was mixed with antigen following the
manufacturer’s instructions before exposing the mix to the cells.
After 2-h incubation at 37◦C and 5% CO2, the cells were washed
three times with PBS pH 7.4. Cell membranes were stained bright
green with wheat germ agglutinin, Alexa FluorTM 488 Conjugate
(WGA-488, Thermo Fisher Scientific), and nuclei were stained
blue with Hoechst 33342 (Thermo Fischer Scientific), following
the manufacturer’s instructions. Cells were visualized using a
40× confocal laser-scanning microscope (LSM510METS, Zeiss).
Microscopy was performed at the Australian Cancer Research
Foundation (ACRF)–Institute for Molecular Bioscience Cancer
Biology Imaging Facility, which was established with the support
of the ACRF.
Imaging and Immunization Studies
Conducted in Mice
Adult BALB/c female mice were purchased from and housed in
the Biological Resource Facility, The University of Queensland,
Brisbane, Australia, under specific pathogen-free conditions.
Eight-week-old female mice were housed in HEPA-filtered cages
with 10 animals per group in an environmentally controlled area
with a cycle of 12 h of light and 12 h of darkness. Food and water
were given ad libitum.
The injectable doses were administered to investigate the
induction of immune responses, and the treatment groups
received injections as mentioned in Table 1. The mineral oil–
based adjuvant Montanide-ISA206 was resuspended with the
formulations of groups 3 and 5. One injection was administered
at start of the experiment (day 0) to all the treatment groups
except for the unimmunized group. Dose volumes of 100 µL (in
0.9% saline, Pfizer) were administered by subcutaneous injection
at the tail base using a sterile 27-gauge needle (Terumo, Tokyo,
Japan). Two animals were imaged and then sacrificed from each
group on days 3, 8, and 13 after immunization. The remaining
four animals were imaged and then sacrificed on day 28.
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TABLE 1 | Immunization groups used in the mice trial.
Group Number Prototype vaccine/injection dose
1 10 Rho-SV140-C18 (2,000 µg)
2 10 Cy5-Bm86 antigen (200 µg) adsorbed to
Rho-SV-140-C18 (2,000 µg)
3 10 Cy5-Bm86 antigen (200 µg) adsorbed to
Rho-SV-140-C18 (2,000 µg) + 50 µL Montanide
ISA206
4 10 Unimmunized
5 10 Cy5-Bm86 antigen + 50 µL Montanide ISA206
All doses (100 µL) were administered subcutaneously at the tail base.
In vivo and ex vivo Imaging of the Live Mice
and Collected Organs
Images were acquired for ventral and dorsal views (supine and
prone position) at each timepoint (3, 8, 13, and 28 days) for
each group of mice. The same acquisition parameters for ex
vivo imaging were used at for each timepoint. Fluorescent—
560-, 580-, 600-, 620-, and 630-nm excitation, each 670 = nm
emission, Auto exposure, 8 × 8 binning, f-stop 2, FOV 22.5 cm
for Cy5, and for Rhodamine 520-, 540-, and 560-nm excitation,
each 620-nm emission. Photography settings were as follows:
0.2-s exposure, no binning, f-stop 6, FOV 22.5 cm, X-ray—0.7-
s exposure, f-stop 2, FOV 22.5 cm. Unmixing was used on all
images, but made little difference in signal-to-noise ratio. This
comparison is shown in the plot for the ex vivo data, as well
as different image sets. Unmixing was done using the in-built
function on Living Image (v4.7.2), and a model was created
from an image of the samples and mouse before injection. Only
background subtraction was applied to the ex vivo image sets,
and no unmixing was applied to ex vivo image sets. Regions of
interest were drawn around background zeroed organs, and the
total radiant efficiency for each organ across a set of mice for
each compound was normalized using the ratios of Cy5 intensity
determined, and control organ was subtracted from the samples,
averaged, and plotted with the standard deviation as the error.
Preimmunization blood samples were collected prior to the
first injection and processed as previously described (Mody
et al., 2014b). Blood samples postvaccination were collected via
cardiac puncture at the respective timepoints. The animals were
weighed and monitored for general health once a week. All the
animals were assessed weekly, and they remained in good health
throughout the duration of the study.
Enzyme-Linked Immunosorbent Assay
Protocol
The detection of total immunoglobulin G (IgG) Bm86-specific
antibodies was performed by coating microtiter plates (96-
well, Nunc, Maxisorb, Roskilde, Denmark) with Bm86 antigen
solution (2 ng/µL, 50 µL per well) in PBS overnight at 4◦C.
The coating solution was removed, and the plates were washed
once with PBS-T (PBS, 0.1% Tween-20, Sigma–Aldrich) and
blocked with bovine serum albumin (5%, Sigma–Aldrich) and
skim milk (5%, Fonterra, Auckland, New Zealand) in 200 µL
PBS for 1 h with gentle shaking at RT. Plates were washed three
times with PBS-T. Mouse sera samples were diluted from 1:100
to 1:6,400 in 50 µL PBS, and each dilution was added to the
wells of the blocked plates followed by incubation for 2 h at
RT. After washing, the mouse antibodies were detected using
a horseradish peroxidase (HRP)–conjugated polyclonal sheep
anti–mouse IgG antibodies (Chemicon Australia, Melbourne,
VIC, Australia) diluted in PBS to 1:40,000, added to each well and
incubated for 1 h at RT with gentle shaking. Plates were washed
three times in PBS-T. TMB substrate (100 µL, Life Technologies)
was added to each well and incubated for 15min at RT; 100 µL of
1N HCl was added to the wells to stop the chromogenic reaction.
The plates were read at 450 nm on the BioTek microplate reader
(Winooski, US).
For the detection of IgG1 and IgG2a antibodies specific to
Bm86 antigen, the following protocol was performed by coating
microtiter plates (96-well, Nunc, Maxisorb, Roskilde, Denmark)
with Bm86 antigen solution (10 ng/µL, 50 µL per well) in
carbonate-bicarbonate buffer (0.1M, pH 9.6) overnight at 4◦C.
The coating solution was removed, and the plates were washed
once with PBS-T (PBS, 0.05% Tween-20, Sigma–Aldrich) and
blocked with bovine serum albumin (2.5%, Sigma–Aldrich) in
200 µL PBS for 2 h with gentle shaking at RT. Plates were washed
three times with PBS-T. Mouse sera samples were diluted from
1:3,200 to 1:6,400 in 50 µL PBS, and each dilution was added
to the wells of the blocked plates followed by incubation for
1.5 h with gentle shaking at RT. Plates were again washed three
times with PBS-T and the HRP-conjugated anti–mouse IgG1
and IgG2a antibodies (Chemicon Australia, Melbourne, VIC,
Australia) diluted in PBS to 1:5,000, added to each well, and
incubated for 1 h at RT with gentle shaking. Plates were washed
three times in PBS-T. TMB substrate (100 µL, Life Technologies)
was added to each well and incubated for 15min at RT; 100 µL of
1N HCl was added to the wells to stop the chromogenic reaction.
The plates were read at 450 nm on the BioTek microplate reader
(Winooski, US).
T test (Giuliano et al., 1999) was used to calculate the mean
values of total IgG, and the graph was plotted at two dilutions
3,200 and 6,400, similarly for IgG1 and IngG2, a mean value was
plotted for 6,400 dilution.
Histopathology
Heart, kidney, lymph node, lungs, liver, and injection sites from
the sacrificed mice were collected and fixed in 10% formalin
for 48 h. The organs were further processed and embedded in
paraffin, and 8-µm sections were cut using the Leica RM 2245
Rotary Microtome. The sections were then stained using the
following hematoxylin–eosin staining procedure. Sections were
first dewaxed in xylene (three changes of 2min each) and then
rehydrated in absolute alcohol (two changes of 2min each),
in 90% for 2min, in 70% for 2min, then washed in running
tap water for 2min and stained in hematoxylin for 3min, and
again washed in running tap water for 2min. Sections were
then washed in 70% alcohol for 2min and stained in eosin for
3min. Sections were then washed in 95% alcohol for 2min and
then in absolute alcohol (three changes of 2min each). Finally,
the sections were rapidly dehydrated and fixed in xylene (three
changes of 2min each) and mounted in DePeX. The sections
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were then observed under the Zeiss LSM 510 META confocal
microscope at 20×magnification.
RESULTS
The SV-140-C18 particles investigated in this study have been
characterized previously (Mody et al., 2016). In this study, the
100 µg of Cy5-Bm86 protein was adsorbed to 1 g of the Rho-
SV-140-C18 vesicles. The SDS–PAGE analyses on the adsorption
samples demonstrated that the integrity of Bm86 protein was
preserved postlabeling (Supplemental Figure 1). Furthermore,
Western blot analysis of the fluorescently labeled nanovaccine
formulation demonstrated the Cy5-labeled Bm86 retained its
native antigenicity as it was recognized by the antibodies in serum
from a sheep immunized with the unlabeled antigen from a
previous study (Figure 1).
Cellular Uptake
The cellular uptake of the antigen Cy5-Bm86 adsorbed to
Rho-SV-140-C18 vesicles was investigated using the murine
macrophage cell line RAW 264.7 cells and confocal microscopy.
In order to study the uptake and intracellular fate of the
labeled antigen and SVs, cell membranes were stained bright
green with wheat germ agglutinin, and nuclei were stained blue
with Hoechst. Cy5 is represented in red, and Rhodamine is
represented in yellow; the colocalization of antigen with SVs
appears orange because of the overlap of red and yellow. As
illustrated in the confocal images (Figure 2), labeled antigen
and SVs were effectively taken up by the cells as shown by
the presence of fluorescence inside the cells compared to the
control group (Figure 2F). Cy5-Bm86 plus Montanide ISA 206
adjuvant and Cy5-Bm86–loaded SV-140-C18 plus Montanide
ISA 206 showed considerably higher fluorescence intensity in the
cells compared to other groups [control (F), Cy5-Bm86 (B), and
FIGURE 1 | Western blotting analysis of Cy5-Bm86 in the vaccine
formulations, lane 1—protein ladder, lane 5—Cy5-Bm86 protein, lane
7—Cy5-Bm86/ Rho-SV-140-C18 Supernatant, lane
8—Cy5-Bm86/Rho-SV-140-C18 pellet (first antibody 869 polyclonal sheep
1:5,000; second antibody monoclonal anti-goat/sheep 1:10,000).
Cy5-Bm86 loaded SV-140-C18 (C)]. Moreover, both the red and
yellow fluorescence overlay to give an orange color in the merged
images for Cy5-Bm86–loaded SV-140-C18, as well as Cy5-Bm86–
loaded SV-140-C18 plus Montanide ISA 206, indicated that both
Cy5-labeled antigen and Rho-labeled SV were taken up by the
RAW 264.7 cells.
In vivo Biodistribution Studies in Live Mice
To track the nanoparticles and antigen in vivo, whole-animal
fluorescence imaging was undertaken. To assess the potential
efficacy of antigen as well as SV as adjuvants, the biodistribution
of both nanoparticles and antigen was evaluated at several
timepoints after one subcutaneous immunization.Whole-animal
fluorescence imaging (Figure 3) clearly demonstrated that most
of the Rho-SV-140-C18 and antigen remained at the site of
injection, with no obvious decrease in fluorescence intensity, for
the duration of the experiment to day 28.
Generation of Total IgG, IgG1, and IgG2a
Antibodies in Response to Bm86 Antigen
To evaluate the capacity of the Cy5-Bm86/Rho-SV-140-C18
and Cy5-Bm86/Rho-SV-140-C18 plus Montanide ISA 206
nanovaccine formulations to elicit immune responses, animals
were immunized with single subcutaneous injections. The total
IgG responses of the immunized mice were analyzed by anti-
Bm86–specific enzyme-linked immunosorbent assays with sera
harvested at days 3 (n = 10), 8 (n = 8), 13 (n = 6), and 28 (n
= 4). The animals in all the treatment groups remained healthy
and in the normal-weight range throughout the trial period
(data not shown). Four showed similar responses on day 13.
However, group 3 induced strong antibody responses at day 28
timepoint, and less mouse-to-mouse variation was observed with
the animals in this group (average OD value of 1.97 ± 0.37 at
6,400 dilution) (Figure 4). The average OD values for groups 2
and 5 were 0.54± 0.74 and 0.17± 0.16, respectively, at the 6,400
dilution. The mice receiving the Rho-SV-140-C18 only (group
1) and the unimmunized group (group 4) showed no detectable
Bm86-specific antibody responses. A stronger IgG1 response was
detected in the mice (n = 4) of group 3 on day 28 compared
with the animals in groups 2 and 5. Low levels of IgG2a-specific
response to Bm86 antigen was also observed in group 3 animals
(Figure 4).
Ex vivo Imaging of the Collected Mice
Organs
To track the movement of the Cy5-Bm86 and Rho-SV-140-
C18 blood, lymph, heart, lungs, liver, spleen, and kidneys were
collected from the sacrificed animals at days 3, 8, 13, and 28
postvaccination. Weak Rhodamine intensities were too low to
accurately determine away from the injection site of the ex vivo
images. Cy5 fluorescent intensity as observed in the Figure 5 was
the highest recorded in the lymph nodes on day 28 of group
3 animals, followed by the groups 5 and 2 animals. Trafficking
of the antigen to the lymph nodes were observed in groups
3, 2, and 5 mice. No significant difference was observed in
the blood, heart, lungs, liver, spleen, and kidney samples in all
the treatment groups compared to the control group. Ex vivo
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FIGURE 2 | Cellular uptake Confocal fluorescence microscopy of RAW 264.7 cells following incubation with different treatments. The images are of (A) Cy5-Bm86
/Rho-SV-140-C18, (B) Cy5-Bm86 antigen, (C) Cy5-Bm86 antigen/Rho-SV-140-C18 + Montanide ISA206, (D) Cy5-Bm86 antigen + Montanide ISA206, (E) cells
alone and (F) Rho-SV-140-C18. Cell membranes were stained bright green with wheat germ agglutinin, Alexa Fluor
TM 488 Conjugate (WGA-488) and nuclei were
stained blue with Hoechst 33342. Cy5 is represented in red and Rhodamine is represented in yellow and the overlap of Rhodamine and Cy5 appears orange due to
an overlap of red and green.
FIGURE 3 | In vivo biodistribution of the fluorescently immunogens from at 72 h and 28 days of BALB/c mice injected with group 1: Rho-SV140-C18 (2,000 µg);
group 2: Cy5-Bm86 antigen (200 µg)/Rho-SV140-C18 (2,000 µg); group 3: Cy5-Bm86 antigen (200 µg) loaded on Rho-SV140-C18 (2,000 µg) + 50 µL Montanide
ISA206; group 4: unimmunized; and group 5: Cy5-Bm86 antigen + 50 µL ISA206. (A) In vivo total radiant efficiency of group 2 animals in Cy5 channel (no significant
difference observed between the different timepoints when assessed by Tukey multiple comparison test. (B) In vivo total radiant efficiency of group 2 animals in
Rhodamine (Rho) channel * <0.05, ** <0.01 as assessed by Tukey multiple-comparisons test.
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FIGURE 4 | Bm86-specific antibody responses in mice at different timepoints. (A) Mean values of total IgG responses of groups 2, 3, and 5 [day 8 (n = 2), 13 (n = 2),
and 28 (n = 4)] animals and (B) mean value of IgG1 and IgG2a response at 6,400 dilution day 28 (n = 4) after one subcutaneous immunization. Error bars represent
one standard deviation. *P < 0.05, ***P < 0.001.
fluorescence imaging (Supplementary Figure 5) on the excised
organs of group 3 mice (n = 2, at each timepoint) on days 3,
8, and 28 showed a large amount of Cy5 signal at the site of
injection and lymph node compared to the mice (n = 2) in the
control group.
Histopathology of Tissue Organs From
Immunized Mouse
Mouse organ and tissue samples were collected from all the
treatment groups at day 28 postvaccination. Histopathology
assessments of sections from skin-injection site, lymph node,
spleen, kidney, liver, and lung demonstrated that administration
of Cy5-Bm86/Rho- SV-140-C18 (group 2), Cy5-Bm86/Rho-
SV-140-C18 plus Montanide ISA 206 (group 3), Cy5-Bm86
plus Montanide ISA 206 (group 5), and SV-140-C18 alone
(group 1) did not have any observable detrimental effects when
compared to similar tissues from unimmunized control mice
(group 4). Briefly, in all of the organ sections, the cells of the
treatment group looked similar to the unimmunized control
group. No granulomas were formed at the site of injection when
injection site samples were collected, and there is no evidence
of inflammation at the injection site of treatment groups as
confirmed by histopathology. There was no evident change in the
thickness of the skin layer relative to the control group. In the
spleen samples, there were no overt changes in the red-to-white
pulp ratio compared to the control group. Similarly, the kidney
and liver samples collected from the animals given the treatment
did not show changes in the blood vessels and shrinkage or
collapse of the blood vessels. Lungs have a variable morphology,
and no signs of cell death, inflammation, or major difference was
observed in the treatment groups compared to the unimmunized
control. In the lymph nodes, no evident signs of infiltration or
cell death was observed between the treatment groups and the
control group (Figure 6).
DISCUSSION
For subunit vaccines to be successful commercially, it is
important that they elicit strong and specific immune responses
and that any adjuvant used are safe (Jin et al., 2019). In
our recent nanoparticle-based vaccine development studies, we
have reported the capacity of SVs as efficient nanocarriers for
adsorption of different antigens targeting varied animal diseases
(Mody et al., 2014b, 2015; Zhang et al., 2016; Zhao et al., 2016).
In these studies, the SV-140 materials displayed an excellent
capacity to act as self-adjuvanting delivery system. The promising
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FIGURE 5 | Ex vivo fluorescent imaging of mouse organs. The graph represents normalized quantitative Cy5 fluorescence and Rhodamine intensity in each organ at
different timepoints. *P < 0.5, **P < 0.01, ***P < 0.001, ****P < 0.0001. Lymph and liver samples were collected at days 3, 8, 13, and 28 postvaccination.
results from SV-140 materials encouraged us to track their
biodistribution to ensure that they are not getting accumulated
inside the mice organs, a requisite for the development of a
successful subunit vaccine.
The cellular uptake of Bm86 antigen conjugated with Cy5
(Cy5-Bm86) and Rho-SV-140-C18 vesicles was first investigated
using confocal microscopy in RAW 264.7 cells. Cy5-Bm86 plus
Montanide ISA 206 adjuvant and Cy5-Bm86 adsorbed to SV-
140-C18 plus Montanide ISA 206 showed considerably higher
fluorescence intensity in the cells compared to other groups.
MSN surface chemistry plays a critical role in influencing the
cellular uptake characteristics. Nanoparticle size affects the in
vivo pharmacokinetics and its cellular interaction (Hoshyar
et al., 2016) Our cellular uptake assay demonstrated that the
fluorescently labeled antigen and the SVs were evenly taken up by
live cells. Therefore, these formulations were further investigated
in an animal trial. This research work for the first time highlights
and tracks the biodistribution characteristics of Rho-SV-140-C18
and of Cy5-Bm86 antigen using live and ex vivo imaging of
BALB/c mice that were administered one dose of vaccination for
up to 28 days.
As highlighted by Li et al. (2010), biodistribution changes
are dependent on nanoparticle properties and interactions with
the living system (Li et al., 2010). In particular, nanoparticle
size affects the biodistribution of nanoparticles throughout the
body (Sonavane et al., 2008; Choi et al., 2011; Dreaden et al.,
2012). Most of the studies in the literature have shown that
size of the particles has an impact on their biodistribution
characteristics; the microparticles remain in the body much
longer than nanoparticles (Faraji and Wipf, 2009). In this study,
most of the SVs are deposited at the site of the subcutaneous
injection and did not get concentrated in different mouse
organs. Faraji and Wipf (2009) also reviewed that microparticles
remained in the mouse spleen and the site of injection for at
least 2 weeks, whereas nanoparticles of the same material were
almost completely cleared in the same time frame (Faraji and
Wipf, 2009). The largest accumulations of nanoparticles typically
occur in the blood, liver, and spleen (Dreaden et al., 2012).
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FIGURE 6 | Histopathology studies of tissue organs from a mouse injected with nanovaccine immunizations. At the end of the experiment, organs fixed in formalin
were harvested from two mice for each treatment group and embedded in paraffin; sections were stained with hematoxylin–eosin stain and imaged at 20×
magnification; skin-injection site, lymph node, spleen, kidney, liver, lung. The arrows on the figure suggest that no obvious differences were observed at cellular levels
in the organs of the treatment groups vs. the control unimmunized group.
Our results have shown the 50 nm Rho-SV-140-C18 was mostly
retained at the site of injection, and minor signal was observed
in the liver, spleen, and kidneys when the nanoparticles were
loaded with antigen. As discussed by Yu et al. (2012), the silica
nanoparticles were likely internalized by the reticuloendothelial
system following physical sequestration in the liver and spleen
(Yu et al., 2012). In the control group injected with only Rho-SV-
140-C18, there was no accumulation of the nanoparticles in liver,
spleen and kidneys.
Literature suggests that silica nanoparticles when
administered via intravenous route were actively excreted
by the mice within a few days, mainly by the urinary tract but
also within feces, due to particle excretion through the biliary
route (Malfatti et al., 2012). However, additional studies have
shown that the silica nanoparticles can be retained in the body
for longer periods of time and can be detected in liver and
spleen up to 8 weeks postinjection (Cho et al., 2009; Huang
et al., 2011; Malfatti et al., 2012). The biodistribution and the
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excretion rate of silica nanoparticles are greatly dependent on
particle size (Cho et al., 2009; He et al., 2011; Yu et al., 2012;
Fu et al., 2013), the particle shape (Decuzzi et al., 2010; Huang
et al., 2011; Yu et al., 2012), and perhaps the gender of the animal
(De Jong et al., 2013). To our knowledge, there no studies that
have investigated the biodistribution properties of SVs when
administered subcutaneously; our study highlights that SVs were
retained at the site of injection and did not get concentrated to
major organs of mice. Further studies are necessary to evaluate
the biodistribution of the SVs for longer duration in order to
determine if their long-term fate differs from the current study.
The presence of Cy5 signal associated with the Bm86 antigen
in the lymph nodes and spleen over multiple weeks is a strong
indicator of the capacity of SVs to enable slow release of the
antigen and to successfully deliver the antigen to elicit immune
responses. The Cy5-Bm86/Rho-SV-140-C18 in combination with
Montanide adjuvant ISA206 induced highest antibody responses,
followed by the group injected with Cy5-Bm86/Rho-SV-140-C18
after a single subcutaneous immunization. It is quite evident that
stronger IgG1 response was elicited by the group 3 animals at
the day 28 timepoint compared to the groups 2 and 5 animals,
similarly some IgG2a response was noticed in the group 3 animals
compared to group 2 and 5. This is a strong indicator that a
single dose of Cy5-Bm86/Rho-SV-140-C18 in combination with
Montanide adjuvant ISA206 generated a stronger (Th2) antibody
response against Bm86 antigen. These results demonstrate the
potential of SV-140 as both efficient vaccine delivery vehicles
and potent adjuvants, in agreement with a previous study (Mody
et al., 2014b).
In summary, we have demonstrated that Cy5-Bm86/Rho-
SV-140-C18 plus adjuvant ISA206 were efficiently taken
up by murine macrophages. In addition, this formulation
elicited strong antibody responses after a single subcutaneous
immunization, and most of the Rho-SV-140-C18 remained at
the site of injection and slighted traced in the liver and spleen
of groups 2 and 3, but mostly the SVs were not trafficked to
other major organs of the mice by day 28. These findings provide
strong evidence that SV-140 nanomaterials were efficiently taken
up by the cells, but also actively act as carriers and adjuvants by
engaging and mediating in the immunology pathways to induce
essential immune responses. Importantly, this study suggests
the SV-140 nanomaterials are a safe vaccine delivery platform.
Furthermore, strong immunological responses were detected,
and no pathological changes were observed at the injection site
or the major organs, thus further proving the potential of SVs
as a promising new generation vaccine adjuvant and delivery
vehicle for the development of safe and effective veterinary
subunit vaccines.
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